Scalper1 News
Hot biotech Sucampo Pharmaceuticals (SCMP) rose more than 10% in early trading Monday after Guggenheim launched coverage with a buy rating, seeing multiple growth drivers ahead. Analyst Louise Chen wrote that Sucampo’s constipation drug Amitiza still has growth potential, despite growing competition from Actavis’ (ACT) and Ironwood ‘s (IRWD) Linzess. She added that further indications and formulations of Amitiza that are in development, along with Scalper1 News
Scalper1 News